The Union Health Ministry has banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs nationwide, citing a lack of therapeutic justification and potential risks to patients, a move intended to protect public health and ensure only scientifically validated medicines are available. This decision, made in compliance with Supreme Court directions, follows a review by an expert committee under the Drugs Technical Advisory Board, which identified these combinations as irrational or potentially harmful across various categories including dermatological, analgesic, antispasmodic, and antibiotic-based formulations, with specific banned examples including Acetyl Salicylic Acid with Ethoheptazine, Dicyclomine with Paracetamol and Clidinium Bromide, and several Amoxicillin and Cefadroxil combinations, all aimed at promoting rational medicine use and strengthening patient safety, with strict implementation orders issued to regulatory authorities.

The Union Health Ministry has banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs nationwide, citing a lack of therapeutic justification and potential risks to patients, a move intended to protect public health and ensure only scientifically validated medicines are available. This decision, made in compliance with Supreme Court directions, follows a review by an expert committee under the Drugs Technical Advisory Board, which identified these combinations as irrational or potentially harmful across various categories including dermatological, analgesic, antispasmodic, and antibiotic-based formulations, with specific banned examples including Acetyl Salicylic Acid with Ethoheptazine, Dicyclomine with Paracetamol and Clidinium Bromide, and several Amoxicillin and Cefadroxil combinations, all aimed at promoting rational medicine use and strengthening patient safety, with strict implementation orders issued to regulatory authorities.

The Union Health Ministry has banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs nationwide, citing a lack of therapeutic justification and potential risks to patients, a move intended to protect public health and ensure only scientifically validated medicines are available. This decision, made in compliance with Supreme Court directions, follows a review by an expert committee under the Drugs Technical Advisory Board, which identified these combinations as irrational or potentially harmful across various categories including dermatological, analgesic, antispasmodic, and antibiotic-based formulations, with specific banned examples including Acetyl Salicylic Acid with Ethoheptazine, Dicyclomine with Paracetamol and Clidinium Bromide, and several Amoxicillin and Cefadroxil combinations, all aimed at promoting rational medicine use and strengthening patient safety, with strict implementation orders issued to regulatory authorities.

The Centre has banned the manufacture, sale and distribution of 16 fixed-dose combination (FDC) drugs across the country. According to PTI, these drug combinations "lack therapeutic justification" and may pose risks to patients. 

The Union Health Ministry said the move is aimed at protecting public health and ensuring that only scientifically validated medicines remain available in the market. 

FDC drugs contain a combination of two or more active pharmaceutical ingredients in a fixed ratio. 

The move comes following a review of the FDCs carried out in compliance with the Supreme Court directions. The Drugs Technical Advisory Board (DTAB) formed an expert committee to examine various drug combinations and identify those considered irrational, therapeutically unjustified, or potentially harmful. 

The committee added that the prohibited formulations cover several therapeutic categories, including certain dermatological preparations, analgesic (painkiller) and antispasmodic (muscle relaxant) medicines, as well as antibiotic-based combinations.

According to public health experts, irrational FDCs often combine medicines that either do not work synergistically or require different dosing schedules, making it difficult for doctors to individualise treatment.

As reportedly explained by Dr Kamini Walia, senior scientist at the Indian Council of Medical Research (ICMR), rational FDCs are backed by scientific evidence showing that the combined drugs improve therapeutic outcomes. In contrast, irrational combinations are marketed without sufficient evidence and may unnecessarily expose patients to multiple drugs.

What are the drugs on the banned list? 

Among the banned drug combinations are Acetyl Salicylic Acid with Ethoheptazine; Dicyclomine, Paracetamol and Clidinium Bromide; Dicyclomine, Paracetamol, Clidinium Bromide and Chlordiazepoxide; Gliclazide with Chromium Picolinate; and Paracetamol with Lignocaine.

Also, several antibiotic-based combinations, including Amoxicillin with Serratiopeptidase, Amoxicillin with Serratiopeptidase and Lactobacillus Sporogenes, Amoxicillin with Cloxacillin, Lactic Acid Bacillus and Serratiopeptidase, Cefadroxyl with Probenecid, and Cefuroxime with Serratiopeptidase, were also banned. 

"The indiscriminate use of irrational antibiotic combinations accelerates antimicrobial resistance. Every unnecessary antibiotic exposure gives bacteria another opportunity to evolve resistance," says Dr Ramesh Shah, family physician based in Mumbai. 

Even some dermatological and skincare formulations containing Aloe Vera or Alo Extract with ingredients like Vitamin E, Jojoba Oil, Orange Oil, Wheat Germ Oil, Tea Tree Oil, Allantoin and D-Panthenol were also prohibited. "These combination creams often suppress symptoms without treating the underlying infection. In fungal diseases, steroids can actually worsen the condition while giving patients a false sense of improvement," says Ruchira Waghle, a dermatologist. 

Their widespread over-the-counter availability has contributed to misuse across the country.

A notification issued by the Centre under Section 26A of the Drugs and Cosmetics Act, 1940, notes that the action is part of the government's efforts to promote the rational use of medicines and strengthen patient safety. 

The Health Ministry has directed the regulatory authorities and enforcement agencies to ensure strict implementation of the notifications. 

Manufacturers, importers, and distributors have been advised to take corrective action to comply with the law. 

(With inputs from Pooja Biraia) 

TAGS